# Klaus Pantel

Source: https://onco.cc/people/klaus-pantel/  
OnCo record `klaus-pantel` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Klaus Pantel is a pioneer of circulating tumour cell research and the liquid biopsy field.

## Summary

Klaus Pantel is Director of the Institute of Tumor Biology at Universitätsklinikum Hamburg-Eppendorf. His specialisms are liquid biopsy, circulating tumour cells and minimal residual disease. His work on disseminated and circulating tumour cells established liquid biopsy as a research discipline, and he coordinated the European CANCER-ID consortium. His Nature Reviews Clinical Oncology paper reviewed liquid biopsy and minimal residual disease, and their implications for cure. He is a pioneer of circulating tumour cell research, working across circulating tumour DNA and molecular residual disease testing. His publications are listed on PubMed.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Director, Institute of Tumor Biology, UKE Hamburg
- Specialisms: Liquid biopsy; Circulating tumour cells; Minimal residual disease

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Pantel%20K%5BAuthor%5D%20circulating%20tumor%20cells

## Connected records

- technologies: [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [MRD / molecular residual disease testing](https://onco.cc/technologies/mrd-testing/)
- institutions: [Universitätsklinikum Hamburg-Eppendorf](https://onco.cc/institutions/uke-hamburg/)
- terms: [Minimal / molecular residual disease (MRD)](https://onco.cc/terms/mrd/)
- journals: [Nature Reviews Clinical Oncology](https://onco.cc/journals/nature-reviews-clinical-oncology/)
- ideas: [A ring-fenced metastasis programme with metastasis-specific endpoints](https://onco.cc/ideas/idea-fund-metastasis-moonshot/), [Circulating tumour cell clearance as the phase 2 gate for anti-metastatic drugs](https://onco.cc/ideas/idea-bio2-ctc-clearance-go-nogo/), [Take the blood test, and give the drug, at the right time of day](https://onco.cc/ideas/idea-bio2-circadian-mrd-sampling/), [Ten-year awards for scientists who commit to one hard problem](https://onco.cc/ideas/idea-fund-ten-year-hard-problem-awards/)
- roadmaps: [ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment](https://onco.cc/roadmaps/ctdna-tests/)

---
JSON: https://onco.cc/api/v1/entities/klaus-pantel.json